In vivo anti-inflammatory and antinociceptive effects of liriodendrin isolated from the stem bark of Acanthopanax senticosus.
In the present study, liriodendrin isolated by activity-guided fractionation from the ethyl acetate (EtOAc) extracts of the stem bark of Acanthopanax senticosus, was evaluated for anti-inflammatory and antinociceptive activities. Liriodendrin (5, 10 mg/kg/day, p. o.) significantly inhibited the increase of vascular permeability induced by acetic acid in mice and reduced an acute paw edema induced by carrageenan in rats. When the analgesic activity was measured by the acetic acid-induced writhing test and hot plate test, liriodendrin showed a dose-dependent inhibition in animal models. In addition, syringaresinol, the hydrolysate of liriodendrin, more potently inhibited the LPS-induced production of NO, PGE 2 and TNF-alpha production of macrophages than liriodendrin. Consistent with these observations, the expression level of iNOS and COX-2 enzyme was decreased by syringaresinol in a concentration-dependent manner. These results suggest that the anti-inflammatory and antinociceptive effects of liriodendrin after oral administration were attributable to the in vivo transformation to syringaresinol, which may function as the active constituent.
Jung
Hyun-Ju
HJ
Division of Applied Plant Sciences, Sangji University, Woosan-Dong, Wonju, Korea.
Park
Hee-Juhn
HJ
Kim
Ryung-Gue
RG
Shin
Kyoung-Min
KM
Ha
Joohun
J
Choi
Jong-Won
JW
Kim
Hyoung Ja
HJ
Lee
Yong Sup
YS
Lee
Kyung-Tae
KT
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D005591:Chemical Fractionation; D051546:Cyclooxygenase 2; D015232:Dinoprostone / Q000096:biosynthesis; D028001:Eleutherococcus / Q000737:chemistry*; D005663:Furans / Q000037:antagonists & inhibitors / Q000302:isolation & purification / Q000494:pharmacology*; D005960:Glucosides / Q000302:isolation & purification / Q000494:pharmacology*; D007527:Isoenzymes / Q000096:biosynthesis; D007723:Korea; D017705:Lignans / Q000037:antagonists & inhibitors; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009569:Nitric Oxide / Q000096:biosynthesis; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II; D010147:Pain Measurement; D024301:Plant Bark / Q000737:chemistry; D018547:Plant Stems / Q000737:chemistry; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005663:Furans; D005960:Glucosides; D007527:Isoenzymes; D017705:Lignans; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; C042192:syringaresinol; D009569:Nitric Oxide; C068512:liriodendrin; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; C496318:Nos2 protein, rat; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone